Literature DB >> 16509593

N-substituted 4beta-methyl-5-(3-hydroxyphenyl)-7alpha-amidomorphans are potent, selective kappa opioid receptor antagonists.

F Ivy Carroll1, Matt S Melvin, Michel C Nuckols, S Wayne Mascarella, Hernán A Navarro, James B Thomas.   

Abstract

In a previous study, we identified (-)-N-[(1R,4S,5S,7R)-5-(3-hydroxyphenyl)-4-methyl-2-(3-phenylpropyl)-2-azabicyclo[3.3.1]non-7-yl]-3-(1-piperidinyl)propanamide (5a, KAA-1) as the first potent and selective kappa opioid receptor antagonist from the 5-(3-hydroxyphenyl)morphan class of opioids. In this study we report an improved synthesis of this class of compounds. The new synthetic method was used to prepare analogues 5b-r where the morphan N-substituent and 7alpha-amido group were varied. Most of the analogues showed sub-nanomolar potency for the kappa opioid receptor and were highly selective relative to the mu and delta opioid receptors. (-)-3-(3,4-Dihydroisoquinolin-2(1H)-yl)-N-{(1R,4S,5S,7R)-5-(3-hydroxyphenyl)-4-methyl-2-[2-(2-methylphenyl)ethyl]-2-azabicyclo[3.3.1]non-7-yl}propanamide (5n, MTHQ) is at least as potent and selective as nor-BNI as a kappa opioid receptor antagonist in the [35S]GTP-gamma-S in vitro functional test.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16509593     DOI: 10.1021/jm058264p

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Duration of action of a broad range of selective κ-opioid receptor antagonists is positively correlated with c-Jun N-terminal kinase-1 activation.

Authors:  Erica J Melief; Mayumi Miyatake; F Ivy Carroll; Cécile Béguin; William A Carlezon; Bruce M Cohen; Sarah Grimwood; Charles H Mitch; Linda Rorick-Kehn; Charles Chavkin
Journal:  Mol Pharmacol       Date:  2011-08-10       Impact factor: 4.436

2.  A new synthesis of the ORL-1 antagonist 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidinyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one (J-113397) and activity in a calcium mobilization assay.

Authors:  Emilie D Smith; N Ariane Vinson; Desong Zhong; Bertold D Berrang; Jennifer L Catanzaro; James B Thomas; Hernán A Navarro; Brian P Gilmour; Jeffrey Deschamps; F Ivy Carroll
Journal:  Bioorg Med Chem       Date:  2007-10-13       Impact factor: 3.641

Review 3.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

4.  The influence of esters and carboxylic acids as the N-substituent of opioids. Part 1: Benzomorphans.

Authors:  Matthew D Metcalf; Mario D Aceto; Louis S Harris; James H Woods; John R Traynor; Andrew Coop; Everette L May
Journal:  Bioorg Med Chem       Date:  2007-10-13       Impact factor: 3.641

Review 5.  Development of κ opioid receptor antagonists.

Authors:  F Ivy Carroll; William A Carlezon
Journal:  J Med Chem       Date:  2013-02-14       Impact factor: 7.446

6.  Flavonoids as opioid receptor ligands: identification and preliminary structure-activity relationships.

Authors:  Peter L Katavic; Kenneth Lamb; Hernan Navarro; Thomas E Prisinzano
Journal:  J Nat Prod       Date:  2007-08-09       Impact factor: 4.050

7.  4β-Methyl-5-(3-hydroxyphenyl)morphan opioid agonist and partial agonist derived from a 4β-methyl-5-(3-hydroxyphenyl)morphan pure antagonist.

Authors:  F Ivy Carroll; Moses G Gichinga; John D Williams; Eyal Vardy; Bryan L Roth; S Wayne Mascarella; James B Thomas; Hernán A Navarro
Journal:  J Med Chem       Date:  2013-11-05       Impact factor: 7.446

8.  Site-Selective Reaction of Enaminones and Enamine Esters for the Synthesis of Novel Diverse Morphan Derivatives.

Authors:  Xing-Mei Hu; Bei Zhou; Chang-Long Yang; Jun Lin; Sheng-Jiao Yan
Journal:  ACS Omega       Date:  2018-06-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.